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Abstract
Purpose We set out to develop a real-time comput-
erised decision support system (CDSS) embedded in
the electronic health record (EHR) with information
on risk factors, estimated risk, and guideline-based
advice on treatment strategy in order to improve ad-
herence to cardiovascular risk management (CVRM)
guidelines with the ultimate aim of improving patient
healthcare.
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Methods We defined a project plan including the
scope and requirements, infrastructure and interface,
data quality and study population, validation and
evaluation of the CDSS.
Results In collaboration with clinicians, data scien-
tists, epidemiologists, ICT architects, and user expe-
rience and interface designers we developed a CDSS
that provides ‘live’ information on CVRM within the
environment of the EHR. The CDSS provides informa-
tion on cardiovascular risk factors (age, sex, medical
and family history, smoking, blood pressure, lipids,
kidney function, and glucose intolerance measure-
ments), estimated 10-year cardiovascular risk, guide-
line-compliant suggestions for both pharmacological
and non-pharmacological treatment to optimise risk
factors, and an estimate on the change in 10-year risk
of cardiovascular disease if treatment goals are ad-
hered to. Our pilot study identified a number of is-
sues that needed to be addressed, such as missing
What’s new?
 Adherence to guidelinesmay improve if these are
shown to patients and their healthcare providers
in an electronic health record.
 Clinical decision support tools that generate pa-
tient-specific assessments or recommendations
may improve practitioner performance without
additional utilisation of healthcare resources if
data are collected in a standardised manner.
 Guidance on scientific evaluation of eHealth
tools is much needed to determine whether im-
plementation cost-effectively improves patient
outcomes.
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data, rules and regulations, privacy, and patient par-
ticipation.
Conclusion Development of a CDSS is complex and
requires a multidisciplinary approach. We identified
opportunities and challenges in our project develop-
ing a CDSS aimed at improving adherence to CVRM
guidelines. The regulatory environment, including
guidance on scientific evaluation, legislation, and pri-
vacy issues needs to evolve within this emerging field
of eHealth.
Keywords Computerised decision support system ·
Cardiovascular risk management · Adherence · Real-
world data · Big data · Health information technology
Introduction
Modification of vascular risk factors is effective in re-
ducing cardiovascular morbidity and mortality in pa-
tients with a cardiovascular condition [1]. Cardiovas-
cular management guidelines provide various recom-
mendations for modification [2]. Yet, there is a gap
between guidelines and practice: adherence to guide-
lines varies between medical disciplines and between
treating physicians, even for similar patients [3]. This
leads to suboptimal risk factor screening and manage-
ment, which eventually leads to preventable excess
morbidity and mortality [4].
Studies suggest that adherence to guidelines im-
proves if attention is drawn to them, for instance
by presenting clinicians with the latest guideline ev-
idence together with individual patient information
‘live’ in the electronic health record (EHR) in an easy
accessible online format [5, 6]. This type of ‘live’
computerised decision support system (CDSS) is an
electronic system designed to aid clinical decision-
making by generating patient-specific assessments
or recommendations that are presented to clinicians.
Also, CDSSs can support benchmarking by detecting
cases where suboptimal decisions were made—i.e.
decisions that did not conform to the latest guide-
lines. As a new component of the clinical infrastruc-
ture, CDSSs may improve processes and practitioner
performance without additional utilisation of health-
care resources, and ultimately results in improvement
of patient outcomes [5, 7].
Here we describe the development and pilot find-
ings of such a CDSS.
Methods
Incentive, scope, requirements, and clinical content
Development of the CDSS started with defining the
project and its incentive. It is well established that
CDSSs developed together with clinicians are used
more frequently than those developed by industry
alone [6, 8]. We created an expert group compris-
ing clinicians, data scientists, epidemiologists, ICT
architects, and user experience and user interface
designers. This expert group defined the scope of our
pilot as a ‘cardiovascular risk management (CVRM)
dashboard in the EHR environment of the University
Medical Centre Utrecht, scalable to other types of
EHR for use in routine clinical practice and accessible
to patients’.
A project plan was drafted defining aims on timing,
content, and functionalities. The CVRM dashboard
should provide the treating physician with ‘live’ infor-
mation in the EHR environment during the patient
visit. The content comprised cardiovascular risk fac-
tors (age, sex, medical and family history, smoking,
blood pressure, lipids, kidney function, glucose intol-
erance), estimated 10-year cardiovascular risk, guide-
line-compliant strategies for (non-)pharmacological
treatment to optimise risk factors, and an estimated
change in 10-year risk of cardiovascular disease (CVD)
if treatment goals are adhered to [1, 9]. It was re-
quested that treatment benefit be incorporated into
the risk calculation in such a way that clinicians and
patients could switch these prospects ‘on’ and ‘off’ to
explore the effects of certain interventions. Risk as-
sessment for CVD is calculated differently for patients
with different (co-)morbidities. These risk factors,
scores, and guideline-compliant strategies together
formed a decision tree with business rules. In these
business rules we determine which risk assessment
methodology to use for patients with different co-
morbidities, such as (1) with no previous cardiovas-
cular events, HEART score; (2) with a history of one
or more cardiovascular events, SMART score; (3) with
diabetes, ADVANCE; and (4) elderly patients, Elderly
score. Each of these methodologies defines treatment
targets, thus suggestions for therapy can be gener-
ated from the profile and risk score combined. The
decision tree was derived from the current cardio-
vascular guidelines. Possible conflicts were discussed
until a consensus was reached in an expert group
comprising 12 cardiovascular specialists.
Administrative support was requested, integrating
a print function and a copy-to-consult function to the
CDSS. Direct links to the manuscripts and guidelines
were added to allow physicians easy access to sources
of evidence for risk scores and treatment recommen-
dations. Lastly, the CDSS had to be accessible via pa-
tient portals.
Infrastructure and interface
The technical framework of a CDSS scopes all techni-
cal aspects from data collection (and storage) to user
interface. This technical blueprint comprises infor-
mation on data location, location and functionalities
of the final application, and connections and steps
in-between. In our project, important criteria for the
selection of a technical structure were (1) visualising
the CDSS within the EHR and (2) sustaining scalabil-
ity. Therefore, we chose a web-based application.
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Fig. 1 Technical infra-
structure. CVRM car-
diovascular risk manage-
ment, EHR electronic health
record, DM diabetes melli-
tus
The practical use of the CDSS is described in Fig. 1.
First, a user logs in to the EHR and opens the patient
record after EHR-based authentication. By clicking
on a link within the EHR, the CDSS is activated. The
connection between the data within the EHR and ap-
plication is established via a URL. Prior to authorising
access three security checks are conducted: a single
sign-on Windows authentication, user authentication
via GET parameters (which guarantees that this user
can access this patient data) and a patient identifier
via an encrypted token.
Data on the cardiovascular risk profile are extracted
from the EHR. Four structured query language (SQL)
queries are used to obtain necessary information from
the EHR. These four queries are aimed at question-
naire information, measurements, laboratory results,
and the medication register.
During the development we used a data lake,
a repository of the required anonymised data in its
natural format and with enough data storage space
and adequate processing speed to develop the CDSS.
After the developmental phase and tests on accuracy
and processing burden of the queries on the EHR, the
dashboard was linked directly to the back end of the
EHR, which made data storage within the data lake
unnecessary. Our application calculated risk scores
and provided suggestions for therapy based on pre-
defined business rules. The application returned the
complete dashboard via a viewer. When treatment
suggestions were made, these were accompanied by
clickable boxes that showed the risk score with or
without the proposed treatment. The application
calculated the risk modification due to the interven-
tion and returned these data to the viewer via an
application program interface.
The expert group decided on essentials and prefer-
ences regarding functionalities and user interface.
The user interface, the part of the CDSS the end-
user finally workswith, was designed taking user expe-
rience, characterised by personalisation, accessibility,
compatibility and overall intuitiveness into account
[10]. The expert group discussed the final interface
layout, taking into consideration that personalisation
of a tool increases uptake amongst end-users, but de-
creases scalability. Patient preferences were studied
by a patient panel (n= 67).
Data quality and study population
In many CDSSs, data obtained during routine clini-
cal practice are the main source of input data. Clin-
ical data are generated by caregivers in the EHRs but
are not primarily intended for further use in either
research or feedback. CDSS quality depends on the
‘raw’ data and so ‘garbage in—garbage out’ illustrates
the problem well [11].
The Centre for Circulatory Health of the University
Medical Centre (UMC) Utrecht initiated the Utrecht
Cardiovascular Cohort (UCC) [12]. All first-time pa-
tients visiting one of the departments of the Centre
for Circulatory Health at the UMC Utrecht for the
evaluation of a symptomatic vascular disease or an
asymptomatic vascular condition are invited to par-
ticipate. Information on the cardiovascular risk fac-
tors data set, based on Dutch CVRM Guidelines, is
collected from all patients at all departments and reg-
istered in a structured format in the EHR. The detailed
methodology has been published elsewhere [12]. All
data used for development of our CDSS were extracted
from the files of patients who gave informed consent
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Fig. 2 Cardiovascular risk management dashboard in the electronic health record. For a detailed description, please see the
Results section
for research including the use of their routine clinical
care data.
Validation
During the dashboard development phase validation
studies were conducted in a test environment, i.e.
a copy of the EHRs. Validation included data com-
pleteness (i.e. defined as the proportion of informa-
tion provided versus information needed) and data
accuracy (i.e. defined as agreement between the value
presented in the dashboard and the ‘raw’ value in the
EHR) [11, 13]. These parameters were assessed for risk
factor levels, risk estimates, and medication prescrip-
tion. In addition, checks were performed on the sug-
gested treatment approach given the risk factor levels
and risk estimates following the 2016 CVRM guide-
line, and the estimates of effect when completely ad-
herent to the suggested treatment approach (e.g. the
estimated absolute risk reduction when smoking was
stopped) [1, 14]. This process was repeated until the
accuracy was 100%.
Evaluation
After validation of the CVRM dashboard prototype, ac-
cess was given for ‘live’ CDSS use, within the EHR en-
vironment, to a limited number of clinicians from in-
side and outside the expert group (n= 7) for feedback
on performance and usability. No formal instructions
were given, apart from using the prototype in routine
care, and no formal itemised questionnaire was used.
Results
Fig. 2 shows the prototype of the CVRM dashboard
presented to the treating physician in the EHR dur-
ing patient visits to the outpatient department. The
CVRM dashboard consists of three parts: risk factors,
risk score, and guideline-adherent treatment strate-
gies. The cardiovascular risk factors were displayed
together with prescribed medications. For example,
if lipid-lowering medication was prescribed, this was
displayed in the dashboard below the LDL cholesterol
value.
The completeness of all required risk factors was
between 88% and 100% for those individuals that were
included in the UCC and who gave written informed
consent. Information on medications was extracted
from the electronic prescription system. The com-
pleteness and accuracy of medication registrations
was the responsibility of the treating clinician.
Ten-year cardiovascular risk estimates were based
on HEART score [1] for those free from previous CVD,
the SMART risk score [9] for those with a previous car-
diovascular event, the Elderly risk score [15] for those
aged 70 years or above, and the ADVANCE risk score
[16] for individuals with diabetes mellitus and no pre-
vious CVD. Some information needed for the risk pre-
diction algorithms (e.g. hsCRP for SMART and urine
protein for ADVANCE) was missing. We used mean
imputation to complete the data.
The usability group suggested showing red and
green bars for the 10-year estimated cardiovascular
risks since the use of common abbreviations and
features (such as red for too high values, green for
appropriate values) decreases user time and increases
efficiency and usability.
The seven physicians that were given access for
use of the prototype were enthusiastic but critical.
Positive aspects were the one-click-away overview at
a glance, the personalised risk score, suggestions for
treatment strategy, and the possibility to make a ‘live’
prediction of the estimated benefit of treatment. Yet,
when information on risk factors was not collected or
recorded in other parts of the EHR than anticipated by
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the queries, values were missing, and consecutive cal-
culation of risk estimates and treatment suggestions
failed. This was particular apparent when patients
were not participating in the UCC. This calls for fur-
ther improvement of the dashboard, specifically in the
case of missing data, before widespread implementa-
tion and evaluation of efficacy. We suggest efficacy
can best be evaluated in a multicentre, prospective,
stepped wedge, cluster randomised trial. This design
combines elements of a standard parallel cluster ran-
domised design (the intervention is applied in clus-
ters) and a before—after design (each cluster switches
to the intervention).
Since CVRM is mostly performed by general prac-
titioners in the Netherlands, the technical design of
our application is suitable for embedding in all kinds
of EHR environments, including those of general prac-
titioners. The next steps are to test our proof-of-con-
cept application in these environments.
Discussion
Summary
We set out to develop a CDSS for use in routine clin-
ical practice in order to improve adherence to CVRM
guidelines with the ultimate aim of improving patient
healthcare. The planning and development started
with writing a project plan to define the scope and re-
quirements with a dedicated multidisciplinary team.
This was followed by data work-up, including qual-
ity checks, development of methods to improve data
completeness, and the writing of business rules to in-
corporate individual variables and models into deci-
sion trees. The technical design was then developed,
incorporating aspects of user experience and interface
design, ICT architecture and programming. Finally,
implementation involved consideration of factors that
influence embedding, ICT support and maintenance,
sustainability, generation of scientific support, and
end-user testing. Based on end-user testing, improve-
ment of the prototype is currently ongoing.
Challenges: missing data and text
A CDSS uses data collected in routine clinical prac-
tice. Whereas most imaging, laboratory, and several
other test result data are structurally placed in prede-
fined locations in the EHR, clinical notes are often un-
structured [17]. This is an important potential source
of inaccurate and/or missing data. For example, sys-
tolic pressure is found in several different fields in the
EHR. This can either be solved at the source (involv-
ing many people in a hospital, calls for education,
training, and feedback) or by using search-engine ap-
proaches that extract these measurements [10].
In medical practice clinical notes, usually free text,
are still the cornerstones of medical reporting, as
these allow flexible registration of clinical reasoning
with case nuances, and the procedure is less time-
consuming [18]. Unstructured text is even worse than
unstructured numerical data, such as blood pressure.
Spelling errors, domain-specific abbreviations, and
idiosyncrasies in a complex context make free text
very difficult to analyse computationally. Although
text-mining algorithms are available, extensive efforts
go into that approach before accurate and complete
data are retrieved. Although general text-mining al-
gorithms are available for use, the approach taken
should be tailored to the specific situation at each
hospital, which hampers scalability.
Missing data, irrespective of its underlying cause,
prohibits use of risk-prediction algorithms. Right now,
in the worst case with no data, we can impute missing
data parameters with the mean from a training data
set and generate the average population estimate. But
this could cause a bias towards the population aver-
age. More advanced statistical approaches for impu-
tations are readily available, but the models for im-
putations on an individual patient level have to be
developed, validated and then integrated in the dash-
board approach such that in the end the dashboard
nearly always works in routine clinical practice (unless
there is too much missing data), provides valid and
adequate information, and also informs the treating
physician which information was missing and was es-
timated using statistical modelling. Presently, within
the CVRM dashboard project we are exploring impu-
tation and machine-learning approaches to arrive at
flexible prediction algorithms and compare the per-
formance of the obtained models with respect to ac-
curacy and impact on clinical decision-making [19].
Prediction rules
Traditionally, prediction rules on cardiovascular events
provide 10-year risk estimates. Yet, risk-factor inter-
ventions usually have a lifelong perspective rather
than a 10-year horizon. Lifetime benefit seems a more
intuitive and understandable measure. Recently, it
has become possible to estimate lifetime risks and in-
dividual treatment benefits with externally validated
risk scores for patients with established CVD (SMART-
REACH risk score) and for patients with diabetes mel-
litus (DIAL score). These scores, as well as 10-year risk
scores, are available at the U-Prevent website (http://
www.U-Prevent.com) [9, 15, 20–23].
Our approach to the development of a CDSS facil-
itates the use of any other prediction rules, e.g. pre-
diction of 30-day mortality, 1-year mortality, or the
balance between risk of haemorrhage and reduction
of ischaemic events.
Clinical impact
Although it is plausible that an appropriate CDSS
leads to improved adherence to guidelines and im-
proved patient care, evidence of clinical benefit in
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this regard seems modest. A recent systematic review
by Groenhof and co-workers reported on 22 studies,
almost all conducted in primary care [24]. We con-
cluded that CDSSs are related to some improvement
in CVRM, but heterogeneity limits overall conclusions.
Since the complexity and application of CDSSs can
vary greatly, there is no one-size-fits-all approach in
testing safety and effectiveness[24].
Moreover, alternative design considerations need
to be taken into account for evaluation. Because of
the risk of contamination in a classical randomised
control trial (RCT) with patients as the randomisation
unit, a cluster randomised trial seems the most com-
mon design in CDSS studies. But sample size calcula-
tions need to allow for intra-cluster correlations. Also,
with heterogeneous clusters, statistical performance
can be lower. A stepped-wedge cluster RCT could be
a solution to this problem: this involves random and
sequential cross-over of clusters from control to inter-
vention until all clusters are exposed [25].
Lastly, other outcomes such as patient experi-
ences—as patient empowerment was positively as-
sociated with CDSS effect—and reasons as to why
clinicians deviate from the guidelines should be eval-
uated [24, 26].
Rules and regulations
The rapid developments in information technology
also need to be addressed from legal and ethical per-
spectives. Currently, CDSSs are defined as a medical
device in the medical device requirements (MDR) of
the European Union [27]. The MDR is the prelude to
the Medical Device Directive that will come into effect
in 2020, indicating that medical software like a CDSS
requires CE certification. The criteria for CE certi-
fication of a CDSS are multi-interpretable, but tools
that provide a diagnosis, prognosis or therapy advice
usually require CE certification. CE-certification pro-
cesses are, however, only minimally adapted to evalu-
ate devices such as CDSS, characterised by a combina-
tion of software, medical evidence (risk scores, other
models) andmedical practice. Guidance, starting with
the developmental phase, by an organ specialising in
CE certification, seems appropriate.
Future potential
In general, CDSSs can be considered as a component
of the clinical infrastructure integrating care, data an-
alytics, scientific evidence, and clinical best practice
(guidelines) [5].
This project showed a proof of concept for applica-
tion of data analytics in clinical care. More advanced
data analytics techniques such as probabilistic data
integrity checks to automatically determine erroneous
data andmachine learning, potentially improving pre-
dictions by learning from complex and non-linear in-
teractions, and previously latent auxiliary variables
[28]. Also, decision-tree formulations may be subop-
timal because they may assume unrealistically simple
situations, whereas in practice patients have multiple
problems and treatments might be based on multiple
guidelines [2, 29]. More flexible decision guidance, in-
cluding mitigation frameworks to allow for concurrent
processing of multiple guidelines and Markov random
field methods are potential solutions to this problem
[29, 30]. Practical implementation and adoption of
such approaches should first be explored.
If accessible for evaluations, CDSSs can provide
data for evaluation of care, including benchmarking
of subgroups of clinicians. Furthermore, a CDSS pro-
vides the opportunity to identify eligible patients for
scientific studies, including pragmatic trials. In this
way, CDSSs contribute to development of a learning
healthcare system: a healthcare system where care
and science are connected via a continuous cycle of
data collection in care, data analytics and evaluation,
interpretation and implementation [31].
Conclusion
Development of a CDSS is complex and requires
a multidisciplinary approach. We identified oppor-
tunities and challenges regarding scope and require-
ments, infrastructure and interface, data quality and
population, and validity. The regulatory environment,
including guidance on scientific evaluation, legisla-
tion, and privacy issues needs to evolve within this
emerging field of eHealth.
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